Contrast-induced nephropathy and nephrogenic systemic fibrosis: Minimizing the risk

Canadian Journal of Urology

Volumn 19, Issue 1, 2012, Pages 6074-6080

  Boncher, Nicholas A ^a   Vricella, Gino J ^a   Smith, Michael ^b   Passalacqua, Matthew ^b   Gulani, Vikas ^b   Ponsky, Lee E ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Computed tomography; Contrast induced nephropathy; Endstage renal disease; Magnetic resonance imaging; Nephrogenic systemic fibrosis

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM;

ALGORITHM; CHEMICALLY INDUCED DISORDER; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMAGE QUALITY; KIDNEY DISEASE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ALGORITHMS; CONTRAST MEDIA; GADOLINIUM; HUMANS; KIDNEY DISEASES; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; RADIOGRAPHIC IMAGE ENHANCEMENT; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84862262232     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Shellock FG, Spinazzi A. MRI safety update 2008: Part 1, MRI contrast agents and nephrogenic systemic fibrosis. AJR Am J Roentgenol 2008;191(4):1129-1139.
2. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 2006;16(12):2619-2621.
3. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 2006;21(4):1104-1108.
4. Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008;21(2):123-128.
5. Bhave G, Lewis JB, Chang SS. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. J Urol 2008;180(3):830-835.
6. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 2008;66(2):191-199.
7. Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol 2008;66(2):160-167.
8. Rodby RA. Dialytic therapies to prevent NSF following gadolinium exposure in high-risk patients. Semin Dial 2008;21(2):145-149.
9. Willicombe M, Cunningham J. Nephrogenic systemic fibrosis: a sufficient reason to avoid gadolinium-based contrast in all patients with renal impairment? Semin Dial 2008;21(2):140-141.
10. Linfert DR, Schell JO, Fine DM. Treatment of nephrogenic systemic fibrosis: limited options but hope for the future. Semin Dial 2008;21(2):155-159.
11. Detrenis S, Meschi M, del Mar Jordana Sanchez M, Savazzi G. Contrast medium induced nephropathy in urological practice. J Urol 2007;178(4 Pt 1):1164-1170.
12. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006;(100):S11-S15.
13. Gruberg L, Mintz GS, Mehran R et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000;36(5):1542-1548.
14. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A metaanalysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll of Cardiol 2006;48(4):692-699.
15. Bartorelli AL, Marenzi G. Contrast-induced nephropathy. J Interv Cardiol 2008;21(1):74-85.
16. Pucelikova T, Dangas G, Mehran R. Contrast-induced nephropathy. Catheter Cardiovasc Interv 2008;71(1):62-72.
17. Bartholomew BA, Harjai KJ, Dukkipati S et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004;93(12):1515-1519.
18. Meschi M, Detrenis S, Musini S, Strada E, Savazzi G. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy. Crit Care Med 2006;34(8):2060-2068.
19. Band RA, Gaieski DF, Mills AM et al. Discordance between serum creatinine clearance for identification of ED patients with abdominal pain at risk for contrast-induced nephropathy. Am J Emerg Med 2007;25(3):268-272.
20. Brigouri C, Marenzi G. Contrast-induced nephropathy: Pharmacological prophylaxis. Kidney Int Suppl 2006;(100):30-38.
21. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004;43(1):1-9.
22. Marenzi G, Assanelli E, Marana I et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006;354(26):2773-2782.
23. Mueller C. Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int Suppl 2006;(100):16-19.
24. Merten GJ, Burgess PW, Gray LV et al. Prevention of contrastinduced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;291(19):2328-2334.
25. Briguori C, Airoldi F, D'Andrea D et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 2007;115(10):1211-1217.
26. Deray G. Dialysis and iodinated contrast media. Kidney Int Suppl 2006;(100):25-29.
27. Mehran R, Aymong ED, Nikolsky E et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44(7):1393-1399.
28. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med 2003;348(12):1123-1133.
29. Solomon R, Barrett B. Follow-up of patients with contrastinduced nephropathy. Kidney Int Suppl 2006;(100):46-50.
30. Perdue PW, Balser JR, Lipsett PA, Breslow MJ. "Renal dose" dopamine in surgical patients: dogma or science?. Ann Surg 1998; 227(4):470-473.
31. Stone GW, McCullough PA, Tumlin JA et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003;290(17):2284-2291.
32. Madyoon H, Croushore L, Weaver D, Mathur V. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv 2001;53(3):341-345.
33. Teirstein PS, Price MJ, Mathur VS, Madyoon H, Sawhney M, Balm DS. Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization. Am J Cardiol 2006; 97(7):1076-1081.
34. Weisz G, Filby SJ, Cohen MG, et al. Safety and performance of targeted renal therapy: the Be-RITe! Registry. J Endovasc Ther 2009; 16(1):1-12.
35. Claussen CD, Banzer D, Pfretzschner C, Kalender WA, Schörner W. Bolus geometry and dynamics after intravenous contrast medium injection. Radiology 1984;153(2):365-368.
36. Dorio PJ, Lee FT Jr, Henseler KP, et al. Using a saline chaser to decrease contrast media in abdominal CT. AJR Am J Roentgenol 2003;180(4):929-934.
37. Schoellnast H, Tillich M, Deutschmann HA, et al. Improvement of parenchymal and vascular enhancement using saline flush and power injection for multiple-detector-row abdominal CT. Eur Radiol 2004;14(4):659-664.
38. Choi SI, George RT, Schuleri KH, Chun EJ, Lima JA, Lardo AC. Recent developments in wide-detector cardiac computed tomography. Int J Cardiovasc Imaging 2009;25(Suppl 1):23-29.
39. Pallwein L, Mitterberger M, Aigner F et al. Diagnostic evaluation of small renal masses: value of contrast-enhanced colour Doppler imaging. BJU Int 2007;99(3):579-585.
40. Gravas S, Mamoulakis C, Rioja J et al. Advances in ultrasound technology in oncologic urology. Urol Clin North Am 2009;36(2): 133-145.
41. Wilson SR, Greenbaum LD, Goldberg BB. Contrast-enhanced ultrasound: What is the evidence and what are the obstacles? AJR Am J Roentgenol 2009;193(1):55-60.
42. Williams DS, Detre JA, Leigh JS, Koretsky AP. Magnetic resonance imaging of perfusion using spin inversion of arterial water. Proc Natl Acad Sci USA 1992;89(1):212-216.
43. de Bazelaire CM, Duhamel GD, Rofsky NM, Alsop DC. MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology 2004;230(3):652-659.
44. Pedrosa I, Alsop DC, Rofsky NM. Magnetic resonance imaging as a biomarker in renal cell carcinoma. Cancer 2009;115(10 Suppl): 2334-2345.
45. Cova M, Squillaci E, Stacul F et al. Diffusion-weighted MRI in the evaluation of renal lesions: preliminary results. Br J Radiol 2004; 77(922):851-857.